Henne Holstege
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Blood-based markers for Alzheimer’s pathology in cognitively healthy centenarians: revealing mechanisms of resistance and resilience
Open Date: 2021-07-01
Close Date: 2024-06-30
Articles (18)
Body mass index (BMI), type 2 diabetes (T2D) and associated cardiometabolic features modify Alzheimer’s disease (AD) risk, yet shared mechanisms remain poorly understood. Using sex- and age-stratified genotyping data for BMI and T2D, we investigate how these traits converge on shared genetic pathways to AD risk. Employing multi-trait, machine learning and single-cell transcriptomics, we identify sex-specific cardiometabolic liability linked to higher BMI-associated risk in women and T2D-driven risk in men. Variant-level analyses reveal AD risk associates with genetically-driven hypotension and hypoglycaemia. We identify 35 putative effector genes in seven independent loci colocalizing between BMI/T2D and AD, mapping to peripheral immune and metabolic tissues and cell-types. Pathway enrichment identifies druggable targets in calcium and potassium channel signaling. Across 81 approved drugs modulating shared risk genes, levosimendan - a calcium sensitizer for heart failure - inhibits tau oligomerization and emerges as a repurposing candidate. These findings elucidate sex-specific cardiometabolic drivers of AD, identify actionable biological pathways, and reveal drug candidates for AD prevention and treatment.
Year:
2026
Defining the molecular natural history of Alzheimer’s disease (AD) is essential for earlier diagnosis and effective therapeutical interventions. Using longitudinal cerebrospinal fluid proteomics from 191 individuals across the AD spectrum, with up to 15 years of follow-up, we identified protein changes that preceded and tracked with development of amyloid-β (Aβ) and/or p-tau181 abnormality over 2.8–6.1 years. Early alterations included SMOC1 and YWHAZ and were enriched for glycolytic, synaptic, and axonal guidance pathways, which remained consistently altered across advancing disease stages. After Aβ and p-tau181 abnormality, 185 proteins progressively decreased with disease worsening, of which a subset of synaptic and axonal proteins including NPTX2, EPHA10 also tracked cognitive decline. Together, our findings can support clinical trial design through accurate effect size estimates, and enable biomarker guided therapeutic targeting across the full pre-amyloid-to-dementia disease continuum.
Year:
2026
Brains from cognitively intact centenarians offer a unique window into mechanisms of neuroprotection. We quantified 3,448 proteins by LC–MS/MS in middle temporal gyrus (MTG) from 88 Alzheimer’s disease (AD) patients, 53 controls (50–99 years) and 49 centenarians (100+). After adjustment for cell type composition, Aβ abundance associated with only five proteins, revealing upregulation of HTRA1, LRP1 and NRXN1 as early AD-associated changes. Conversely, tau abundance associated with ∼20% of the quantified proteome, revealing GPRIN1 as the top tau-associated protein. One-third of centenarians had high Aβ abundance, often with Braak neurofibrillary tangle stages IV/V, yet all maintained low local tau abundance. Centenarians showed maintained proteostasis (low ubiquitin peptides, high proteasome components), high PCSK1 (prohormone maturation), high PFKFB2 (glycolysis regulation), mitochondria-coupled lipid β-oxidation and lower APOE levels. Together, these findings suggest a model of neuroprotection in which Aβ facilitates tau seeding, and where proteostatic and metabolic adaptations buffer against additional tau accumulation in centenarians.
Year:
2026
The Alzheimer’s disease (AD) genetic landscape identified microglia as a key disease-modifying cell type. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is an immunoreceptor tyrosine–based inhibitory motif domain–containing inhibitory receptor, expressed by myeloid cells such as microglia. The known protective PILRA G78R gene variant reduces AD risk in apolipoprotein E4 ( APOE4 ) carriers and is enriched in a cohort of healthy centenarians. However, mechanisms underlying protective effects in microglia are undefined. Here, we identified biological functions of PILRA in human induced pluripotent stem cell–derived microglia (iMG) and chimeric AD mice. PILRA knockout (KO) in iMG rescued ApoE4-mediated immunometabolic deficits and prevented lipotoxicity through increased lipid storage, improved mitochondrial bioenergetics, and antioxidant activity. PILRA KO also enhanced microglial chemotaxis and attenuated inflammation. With pharmacological inhibitor studies, we showed that peroxisome proliferator–activated receptor and signal transducer and activator of transcription 1/3 mediated PILRA -dependent microglial functions. AD mice transplanted with human PILRA KO microglia exhibited reduced amyloid pathology and rescued synaptic markers. A high-affinity ligand blocking PILRA antibody phenocopied PILRA KO iMG. These findings suggest that PILRA is a pharmacologically tractable therapeutic target for AD.
Year:
2025
Background As part of the retromer, sortilin-related receptor (SORL1) sorts cargo proteins away from the endosome to the trans-Golgi network or to the cell surface, where SORL1 is cleaved into sSORL1 and shed into the interstitial fluid and CSF. SORL1’s cargo includes APP and Aβ, which may explain why protein-truncating genetic variants (PTVs) in SORL1 are observed almost exclusively in Alzheimer’s Disease (AD) patients, and that rare, predicted pathogenic missense variants have been associated with a 10-fold increased risk of AD. However, functional evidence supporting variant pathogenicity is warranted. Here we investigated whether soluble SORL1 (sSORL1) concentrations in cerebrospinal fluid (CSF) offer a potential in vivo biomarker to support impaired SORL1 function in variant carriers. Methods Using an ELISA assay for SORL1 (ABCAM), we determined sSORL1 concentrations in CSF from 218 participants of the Alzheimer Dementia Cohort (ADC) (54% females). We compared sSORL1 in CSF derived from 90 carriers of diverse SORL1 variants with concentrations observed in 78 SORL1 -WT AD patients, and 50 SORL1 -WT controls for whom CSF-pTau-181, CSF-tTau, CSF-Aβ42 concentrations were available. In a subset of 36 individuals, we used Western blotting (WB) to validate sSORL1 concentrations as determined by ELISA. Results CSF-sSORL1 concentrations did not differ between SORL1 -WT AD patients and controls. While CSF-sSORL1 did not correlate with CSF-Aβ42 concentrations in SORL1 -WT AD patients (p=0.62), it correlated with sCSF-ptau-181 (p=9.7×10 −6 ). The mean CSF-sSORL1 concentration in the SORL1 WT AD cases and controls was 466 pg/ml, with wide variance (SD = 133). Comparatively, concentrations were significantly lower in PTV carriers (260 pg/ml, p=3.2×10 −7 ) and in carriers of predicted damaging SORL1 missense variants (323 pg/ml, p=2.4×10 −7 ). CSF-sSORL1 concentrations measured by ELISA correlated strongly with concentrations estimated by WB (ρ=0.552; p=5.0×10 −4 ). Conclusion CSF-sSORL1 increases with CSF-ptau, suggesting that increased SORL1-retromer activity may serve to rescue cellular stress associated with AD-related processes. However, impairing SORL1 genetic variants may preclude SORL1 trafficking to the cell surface, as supported by lower CSF-sSORL1 protein concentrations in carriers. While further refinements are necessary, we present first evidence for the applicability of ELISA-based quantification of sSORL1 in CSF to evaluate the functional impact of rare SORL1 variants.
Year:
2025
We constructed a polygenic protective score specific to Alzheimer’s disease (AD PPS) based on the current literature among the participants enrolled in five studies of healthy aging and extreme longevity in the US, Europe, and Asia. This AD PPS did not include variants on Apolipoprotein E (APOE) gene. Comparisons of AD PPS in different data sets of healthy agers and centenarians showed that centenarians have stronger genetic protection against AD compared to individuals without familial longevity. The current study also shows evidence that this genetic protection increases with increasingly older ages in centenarians (centenarians who died before reaching age 105 years, semi-supercentenarians who reached age 105 to 109 years, and supercentenarians who reached age 110 years and older). However, the genetic protection was of modest size: the average increase in AD PPS was approximately one additional protective allele per 5 years of gained lifetime. Additionally, we show that the higher AD PPS was associated with better cognitive function and decreased mortality. Taken together, this analysis suggests that individuals who achieve the most extreme ages, on average, have the greatest protection against AD. This finding is robust to different genetic backgrounds with important implications for universal applicability of therapeutics that target this AD PPS.
Year:
2025
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.
Year:
2025
Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.
Year:
2025
We conducted a comprehensive protein quantitative trait loci (pQTL) analysis on a unique set of Gyrus Temporalis Medius (GTM) samples obtained from 88 Alzheimer’s Disease (AD) patients, 53 non-demented individuals, and 49 cognitively healthy centenarians. This investigation revealed 8,081 genetic variants associated with the abundance of 227 proteins, including several novel variant-protein links not identified in a prior pQTL study of the prefrontal cortex or expression QTL (eQTL) analysis across 12 brain regions (GTEx). Among all the AD risk variants tested for possible pQTL effects, only rs429358-T (which encodes the APOE4 allele) was significantly linked to higher APOE levels in the GTM, potentially explaining why this region is particularly prone to AD pathology. Further, through differential correlation analysis we identified AD risk variants linked to altered protein-protein correlations, specifically rs9381040 in TREML2, rs34173062 in SHARPIN, and rs11218343 near SORL1. Notably, DDX17 appears to play a protective role in individuals with the rs9381040-T/T genotype by tightly regulating synuclein levels. Collectively, these findings demonstrate that AD risk variants disrupt protein–protein interactions, highlighting a genetic basis for the coordinated modulation of protein networks in AD.
Year:
2025
Genome-wide association studies (GWAS) linked TMEM106B variants to susceptibility for neurodegenerative diseases, but the causal genetic elements remain unclear. Genotyping of 5,792 Alzheimer disease cases and controls revealed that the TMEM106B locus consists of four major haplotypes: HA/Ha (covering the coding region), and HB/Hb (covering the upstream regulatory region). These combine into four combinations with varying population-frequencies: HAB (57%), HaB (34%), Hab (9%), and HAb (<1%). Long-read sequencing of 513 individuals showed that HA haplotypes (marked by 185-Threonine) carry unique methylated CpG sites and an AluYb8-retrotransposon in the 3’ UTR, while the Ha haplotypes are marked by the 185-Serine allele. Hb haplotypes carry several structural variants (SVs) in nearby distal enhancers, including a 19 Kbp rearrangement, absent in all other haplotypes. Joint association models revealed that the HAB combination (AluYb8+185-Threonine) is risk-increasing, while Hab (SVs+185-Serine) confers the protective effect. HaB (185-Serine only) is neutral, while HAb was too rare to assess. Indeed, relative to middle-aged non-demented controls, cognitively healthy centenarians were more enriched with Hab (OR=1.49, p adj =2.18×10 -2 ) than with HaB (OR=1.23, p adj =5.06×10 -2 ). Finally, proteomic analysis of temporal cortex tissues (n=182) indicated that relative to the neutral HaB combination, the protective Hab is associated with 0.91-fold lower TMEM106B C-terminal peptide abundance (CI=[0.81-1.02]), while the risk-increasing HAB is associated with 1.07-fold higher abundance (CI=[0.99-1.15]). Together, this presents a complex genetic structure underlying the association of the TMEM106B locus with neurodegenerative diseases. ONE SENTENCE SUMMARY GWAS and long-read sequencing suggests that the neurodegenerative genetic etiology associated with TMEM106B is conferred by multiple independent haplotypes.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (105)
Stefanie Heilmann-Heimbach
Head of Laboratory, Research Group Leader
University Hospital Bonn
Ruth Frikke-Schmidt
Professor, Chief Physician, MD PhD DMSc
-
Olivia Belbin
Assistant Professor
Hospital de la Santa Creu i Sant Pau
Maria Jesús Bullido Gómez-Heras
Researcher
Universidad Autónoma de Madrid
Pau Pastor
Institut Català de la Salut
Eloy Rodriguez-Rodríguez
Instituto de Investigación Marqués de Valdecilla
innocenzo rainero
University of Turin
Henrik Zetterberg
Professor
University of Gothenburg
Agustín Ruiz Laza
Director of the Biology Core
University of Texas Health Science Center at San Antonio
Harro Seelaar
Neurologist
Erasmus MC
Philippe Amouyel
Full Professor
Centre Hospitalier Régional Universitaire de Lille
Jesper Qvist Thomassen
Senior Scientist
Rigshospitalet
Marcel Reinders
Delft University of Technology
Johannes Kornhuber
-
Ruth Loos
The Charles Bronfman Professor in Personalized Medicine
Københavns Universitet
Richard Redon
INSERM
Marco Spallazzi
Adjunt professor
University of Parma
Markus Nöthen
Professor, Director
University Hospital Bonn
Benedetta Nacmias
University of Florence
Suzanne Schindler
Associate Professor
Washington University in St. Louis
Lucilla Parnetti
Professor of Neurology
University of Perugia
Caroline Jonson
University of California, San Francisco
Pieter Jelle Visser
Karolinska Institutet
Olav M. Andersen
Aarhus University
Jordi Pérez-Tur
Coordinador Adjunto al Área Global Vida
Agencia Estatal Consejo Superior de Investigaciones Científicas
Mieke M. van Haelst
Prof.dr
Amsterdam University Medical Centers
Patrizia Mecocci
Director
Karolinska Institutet
Mathew Blurton-Jones
Professor
University of California, Irvine
Caroline Graff
Professor,MD PhD
Karolinska Institutet
Henna Martiskainen
University of Eastern Finland
Annemieke J.M. Rozemuller
Professor Neuropathology
-
Amy Kit Yu Fu
Research Professor
The Hong Kong University of Science and Technology
Arvid Rongve
Professor
University of Bergen
Jean-Charles Lambert
Head of research unit
INSERM
Betty Tijms
Senior researcher
VU medisch centrum
Martijn Huisman
University of Amsterdam
Simon Laws
Professor
Edith Cowan University
Nancy Yuk-Yu Ip
The Morningside Professor of Life Science
The Hong Kong University of Science and Technology
Katja Scheffler
Associate Professor
Norwegian University of Science and Technology
Julien Chapuis
Université de Lille
Roos Jutten
Vrije Universiteit Amsterdam
Takeshi Ikeuchi
Professor
Brain Research Institute, Niigata University
Jonathan Vogelgsang
Harvard University
Ciyang Wang
Washington University in St. Louis
Geir Selbaek
Professor
University of Oslo
Timothy Hohman
Professor
Vanderbilt University Medical Center
Aarno Palotie
University of Helsinki
Pablo Mir
-
Charlotte Teunissen
University of Amsterdam
Norbert Scherbaum
Professor for Clinical Addiction Research
University of Duisburg-Essen Faculty of Medizin
Tormod Fladby
Professor ll of Neurology
University of Oslo
Margda Waern
University of Gothenburg
Muhammad Ali
Assistant Professor
Washington University in St. Louis
Lisa Vermunt
Assistant professor
University of Amsterdam
Andrew Saykin
Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
Frank Koopmans
University of Amsterdam
Erik A. Sistermans
-
Srdjan Djurovic
Professor at University of Oslo
University of Oslo
Sami Heikkinen
Research Director
University of Eastern Finland
Najaf Amin
Associate Professor
University of Oxford
Wiesje van der Flier
Scientific director
VU medisch centrum
Peter Holmans
Professor of Biostatistics and Genetic Epidemiology
Cardiff University
Hayk Davtyan
Reserach Professor
University of California, Irvine
David M. Holtzman
Washington University School of Medicine
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
Alessio Squassina
Dalhousie University
Carole Dufouil
Director of research
INSERM
Virginia M-Y Lee
Professor
University of Pennsylvania
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Martin Ingelsson
Specialist
Uppsala University Hospital
Hilkka Soininen
Kuopio University Hospital
María José Romero Lado
University of Copenhagen
Gael Nicolas
PUPH
University of Rouen
Shahzad Ahmad
Staff Scientist
University of Oxford
Riccardo E Marioni
University of Edinburgh
Devrim Kilinc
Institut Pasteur de Lille
Anssi Lipponen
University of Eastern Finland
Avishek Roy
Karolinska Institutet
Patrick Kehoe
Academic , Gestetner Professor of Translational Dementia Research
University of Bristol
Alison Goate
Professor and Chair
Icahn School of Medicine at Mount Sinai
Alfredo Ramirez
University of Texas Health Science Center at San Antonio
INGVILD SALTVEDT
Professor
Norwegian University of Science and Technology
Jean Paul Chadarevian
University of California, Irvine
Dag Aarsland
Professor and Head of Department
King’s College London
Yolande A.L. Pijnenburg
-
Daniela Galimberti
Associate Professor
Università degli Studi di Torino
Carlos Cruchaga
Professor
Washington University in St. Louis
Ole A. Andreassen
Oslo University Hospital
Lucio Tremolizzo
Associate Professor of Neurology
University of Milano-Bicocca
Suzanne Miedema
University of Amsterdam
Valentina Escott-Price
Professor
Cardiff University
Ville Leinonen
Professor
University of Eastern Finland
Lutz Froelich
Head
Zentralinstitut für Seelische Gesundheit
Rebecca Sims
Senior Research Fellow
Cardiff University
Simon Mead
Deputy Director
University College London
Barbara Borroni
Docenti di ruolo di IIa fascia
University of Brescia
Florence Pasquier
Professor
Université de Lille
Lars Bertram
Professor of Genome Analytics
University of Lübeck
Jose Luis Royo
University of Malaga
Mikko Hiltunen
University of Eastern Finland
Cornelia Van Duijn
Professor
University of Oxford
Alberto Lleó
Director
Hospital de la Santa Creu i Sant Pau
Sterling Johnson
Professor
University of Wisconsin-Madison
Menghan Liu
Washington University in St. Louis
Tuomas Kilpeläinen
Assistant professor
Københavns Universitet
Make your next move.
Prepare your application
Review drafts before you send them.